Transglutaminase 3 Reduces the Severity of Psoriasis in Imiquimod-Treated Mouse Skin. by Piro, Maria Cristina et al.
 International Journal of 
Molecular Sciences
Communication
Transglutaminase 3 Reduces the Severity of Psoriasis
in Imiquimod-Treated Mouse Skin
Maria Cristina Piro 1, Alessandra Ventura 2 , Artem Smirnov 1,† , Andrea Saggini 1,‡,
Anna Maria Lena 1, Alessandro Mauriello 1, Luca Bianchi 3, Gerry Melino 1,4 and
Eleonora Candi 1,5,*
1 Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, 00133 Rome, Italy;
piro@med.uniroma2.it (M.C.P.); art.smirnow@gmail.com (A.S.); andreasaggini@gmail.com (A.S.);
lena@med.uniroma2.it (A.M.L.); alessandro.mauriello@uniroma2.it (A.M.);
gm614@mrc-tox.cam.ac.uk (G.M.)
2 Dermatology Unit, Department of Biotechnological and Applied Clinical Science, University of L’Aquila,
IT-67100 L’Aquila, Italy; alessandraventura@live.it
3 Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy;
luca.bianchi@uniroma2.it
4 Medical Research Council, University of Cambridge, Cambridge CB21QP, UK
5 IDI-IRCCS, Biochemistry laboratory, 00167 Rome, Italy
* Correspondence: candi@uniroma2.it; Tel.: +39-06-72596976
† Current address: Ludwig Institute for Cancer Research, University of Oxford, Oxford OX3 7DQ, UK.
‡ Current address: Dermatopathologie laboratory, Friedrichshafen, Germany.
Received: 14 January 2020; Accepted: 24 February 2020; Published: 25 February 2020


Abstract: Four transglutaminase (TG) isoforms have been detected in epidermal keratinocytes: TG1,
TG2, TG3, and TG5. Except for TG1 and TG3, their contribution to keratinocyte development
and structure remains undefined. In this paper, we focused on the roles of TG2 and TG3 in
imiquimod-induced psoriasis in mouse skin. We evaluated the severity of psoriasis markers in the
skin of imiquimod-treated TG3 null and TG2 null mice. Our results showed that compromised TG3KO
mouse skin was more responsive than WT or TG2KO mouse skin to the action of the pro-inflammatory
drug imiquimod.
Keywords: transglutaminase 2; transglutaminase 3; psoriasis; imiquimod; inflammation; skin;
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1. Introduction
Transglutaminases (TGs) are a class of Ca+-dependent enzymes that catalyse protein crosslinking
by the formation of a covalent bond between an amine donor, often a peptide-bound lysine, and the
γ-carboxamide of a glutamine side chain of selected proteins. Originally described in 1959 in guinea
pig liver, TGs play a central role in the creation and reinforcement of epithelial barriers, while at the
extracellular level, they consolidate the extracellular matrix or stabilize fibrin clots [1,2]. The TG family
now encompasses nine members, and TG1, TG3, and TG5 are expressed in the epidermis and are
known to be active in the formation of the cornified cell envelope (CE), a highly insoluble lipid-protein
structure that is present in terminally differentiated keratinocytes and is necessary for the barrier
function of the epidermis [3]. In suprabasal keratinocytes proteins such as loricrin, filaggrin, involucrin,
and trichohyalin, small proline-rich proteins and keratins are crosslinked by TG1, TG3, and TG5 [4,5].
Because of their critical and primary role in the formation of cutaneous barriers, defects in the
genes for TG1, TG3, and TG5 cause important impacts on the integrity and function of the epidermis
and might also manifest as congenital skin or hair diseases. Tgm1 mutations in humans are the
molecular basis of autosomal recessive lamellar ichthyosis [6,7], a skin disorder that is characterized by
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hyperkeratosis and impaired cornification of the epidermis. TG1KO mouse are neonatal lethal and
show an ichthyosis–like phenotype [8]. Acral peeling skin syndrome is derived from TGM5 impairing
mutations [9]. In this disorder, the stratum corneum and granulosum of the epidermis are critically
disjointed [10]. TG5KO mouse have not been developed so far. Finally, a mutation in the TGM3 gene
seems to be responsible for human uncombable hair syndrome (UHS) [11], whereas ablation of the
TG3 gene in mice causes abnormal hair fiber morphogenesis [12].
TG3 is expressed in the hair follicle and in the granular and spinous layers of the epidermis [13,14].
In addition to its involvement in hair development, TG3 also contributes significantly to the proper
formation of the cutaneous barrier because TG3KO mice skin displays increased permeability and
susceptibility to the hapten fluorescein isothiocyanate (FITC) [15]. Moreover, our recent murine study
demonstrated the importance of TG3 crosslinking activity in protecting skin from UV damage [16].
Impaired epidermal structure in TG3KO animals failed to shield against UVB radiation which thus
penetrates deeper through the lower layers of epidermal keratinocytes, reaching the dermis and
provoking high levels of DNA damage and apoptosis.
A fourth enzyme, TG2, is widely diffused in various tissues and cell types. In the skin, TG2 is localized
in dermal fibroblasts, and it is detected in basal keratinocytes only in specialized conditions such as wound
healing and repair [17,18]. However, according to other authors, TG2 is constitutively expressed in all
epidermal layers [19]. TG2 is thought to play a minor role in keratinocyte CE assembly, since mice lacking
TG2 are viable, phenotypically normal, and do not show skin barrier defects [20–22]. TG2 also shows
other mutually exclusive, peculiar enzymatic properties such as GTPase [23], protein disulfide isomerase
(PDI) [24], and protein kinase activities [25]. In the extracellular space, TG2 acts as protein scaffold to
assemble ECM (extracellular matrix) proteins or as a cellular signalling intermediate when it is attached to
the cell membrane [26]. TG2 performs a wide range of cellular and tissue functions, often with opposite
outcomes, such as proliferation, apoptosis, differentiation, or autophagy [27]. Although TG2 does not
seem to play a central role in the epidermis, it is well known to have powerful pro-inflammatory actions,
not only in autoimmune pathologies such as celiac or Crohn’s disease, but also in chronic inflammatory
diseases involving fibrosis generation in the lung, liver, or kidneys [28–32]. Moreover, TG2 activates
the transcription factor NF-kappaB, which positively controls various genes involved in immune and
inflammatory responses and in the production of pro-inflammatory cytokines and chemokines [33,34]. In
this regard, TG2 has been recently proposed as a mediator of the epidermal inflammatory response to UV
radiation. In WT keratinocytes, UV irradiation activates TG2, which in turn induces the expression of
inflammatory cytokines such as TNF-α and IL6. Upon UV exposure, TG2 null mice display decreased
skin inflammation compared to that of WT mice [19].
Psoriasis is an autoimmune and inflammatory skin disease for which the complex genetic
architecture has not yet been well defined [35]. Psoriasis affects 2%-3% of the global population [36]
and can produce various phenotypes with different levels of severity and skin barrier impairment.
The most common phenotype is psoriasis vulgaris, in which abnormal keratinocyte differentiation
leads to the formation of skin plaques with a thickened epidermis (acanthosis), retention of nuclei in
the stratum corneum (parakeratosis), and inflammatory infiltration in the dermis and epidermis [35,37]
Although TG1, TG2, TG3, and TG5 play pivotal roles both in skin barrier structure and/or
inflammatory processes, the contribution of their activities as causes and effects of psoriatic disease
remains elusive. Topical application of imiquimod, a ligand of TLR7 and TLR8, induces a psoriasis-like
skin inflammation with typical microscopic and macroscopic psoriatic markers in mice, and is the most
commonly used psoriasis animal model [38].
We aimed to evaluate whether ablation of the TGM2 or TGM3 gene affected the severity of
psoriasis markers in the context of imiquimod-treated TG3 and TG2 null mice. Our data showed that,
at the microscopic but not macroscopic level, compromised TG3KO mouse skin was more responsive
than WT or TG2KO mice skin to the action of the pro-inflammatory drug imiquimod. In contrast,
TG2 was not relevant to imiquimod-induced psoriatic inflammation.
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2. Results
2.1. Both TGM1 and TGM3 Are Upregulated in Skin from Patients with Psoriasis
First, we investigated TG1, TG2, TG3, and TG5 mRNA expression levels in skin biopsies from
58 psoriasis patients, analyzing publicly available gene array data from the Gene Expression Omnibus
(GEO) repository (Accession number: GSE13355). We observed a strong and significant upregulation
in TG1 and TG3 expression in skin samples with involved lesional (PL) psoriasis (2- and 4-fold,
P = 7 × 10−43 and P = 1 × 10−26, respectively) when compared to those of the involved non-lesional
psoriasis (PN) and normal (N) skin samples. In the same array, no significant changes in TG2 and TG5
genes were observed in PL skin samples compared with those of PN and N skin samples. (Figure 1A,B).
Since TG1KO mice are neonatal lethal [8], we then focused on TG3 to assess its role in psoriasis
development. Additional analysis of human gene array data confirmed a significant increase in TG3
mRNA levels in human psoriatic skin samples (Figure 1D). We then expanded our TG3 bioinformatic
analysis to an imiquimod-induced psoriasis model in C57BL/6 mice, using TG2 mRNA levels as
a control, since TG2 expression is consistent within psoriasis-affected skin samples. As expected,
a significant increase in TG3 mRNA levels was detected in murine psoriatic samples, whereas TG2
mRNA levels remained constant (Figure 1C).
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Figure 1. TGM1 and TGM3 are upregulated in skin samples from psoriasis patients. (A) Heat map 
showing the expression levels of TGM1, TGM2, TGM3, and TGM5 in normal human skin (N), 
uninvolved non-lesional (PN), and involved lesional (PL) psoriasis skin. The expression values were 
obtained from NCBI GEO (Accession number: GSE13355). (B) Box plot showing the distribution of 
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Figure 1. TGM1 and TGM3 are upr gulated in ski samples from psoriasis patients. (A) Heat m p showing
the express on lev ls of TGM1, TGM2, TGM3, and TGM5 in normal human skin (N), uninvolved non-lesional
(PN), a d involved lesional (PL) psoriasis skin. The expression values wer obtained from NCBI GEO
(Accession number: GSE13355). (B) Box plot showing the distribution of expression values of TGM1, TGM2,
TGM3, and TGM5 in PN and PL samples from (A). (C) Analysis of the expression of Tgm2 and Tgm3 in
murine skin treated with imiquimod. Expression values were obtained from NCBI GEO (Accession number:
GSE27628). (D) Analysis of TGM3 expression in normal and psoriatic skin. The expression values were
obtained from NCBI GEO (Accession numbers: GSE6710, GSE14905, GSE78023, and GSE63741).
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2.2. Macroscopic Severity Markers of Psoriasis Display Similar Values in Imiquimod-Treated TG3KO, TG2KO,
and Wild-Type Mice
Topical application of imiquimod on the shaved back skin of C57BL/6 TG3KO and TG2KO mice
for 10 days induced psoriasis-like lesions, such as redness, scales, desquamation, and crust formation
(Figure 2A). As shown macroscopically in Figure 2B, the levels of desquamation and crusts were
comparable in all imiquimod-treated TG3KO, TG2KO, and wild-type animals. Psoriatic skin from the
three groups presented consistent grades in two out of three markers that are commonly utilized to
grade psoriasis severity [39]. As shown in Figure 2C, the scores for erythema (redness), desquamation
(scale), and their cumulative score for TG3KO mice during imiquimod application were not significantly
different compared to the same psoriatic marker values for TG2KO or WT mice.
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Figure 2. Imiquimod-treated TG3KO, TG2KO, and WT mice show similar macroscopic psoriasis
severity grades. (A) Workflow of the study. (B) Photographs showing control nd imiquimod-treated
WT, TG2KO, and TG3KO mice. (C) Analysis of scale, erythema, and cumulative score u ing
imiquimod treatment.
2.3. Imiquimod-Treated TG3KO Mouse Skin Shows Increased Epidermal Thickness and a Slightly Higher Grade
of Basal Keratinocyte Proliferative Activity than Those of TG2-KO and WT Mice
Histological evaluation of skin sections from wild-type, 2 , and TG3KO mice treated with
imiquimod for ten days revealed characteristic alterations in psoriasis lesions, such as acanthosis
(thickening of the epidermis), parakeratosis (presence of nuclei in the stratum corneum), desquamation,
and dermal infiltrates. Interestingly, we observed a significant increase in the thickness of psoriatic
TG3KO mouse epidermis (40 µM) compared to that of the TG2KO and WT psoriatic epidermis (<30 µM).
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Imiquimod application had increased qualitative and quantitative effects on TG3KO mice, including
pustules, increases acanthosis, desquamation, and parakeratosis (Figure 3A). Imiquimod effects in the
three animal groups were confirmed by IL-22 and IL-17a immunostaining, shown in Figure S1.
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Figure 3. Loss of TG3 leads to epidermal thickening upon imiquimod treatment. Scale bar 100 µM.
(A) H&E staining of the skin of either control or imiquimod-treated WT, TG2KO, and TG3KO mice.
The graph shows the measurement of epidermal thickness. (B) Immunohistochemical staining for Ki67
in the skin of imiquimod-treated WT, TG2KO, and TG3KO mice. The graph shows the quantification of
the percentage of Ki67-positive basal cells.
Thus, imiquimod-treated mice presented apparent dysregulated hyperproliferation of
keratinocytes compared to that of the controls in each group. Hyperproliferation of basal keratinocytes
was also monitored by Ki67 immunohistochemical analysis. Ki67 is a cell proliferation marker, and in
imiquimod-treated mi e, Ki67 stai ing was slightly increased in the basal epidermal layer of TG3-KO
mice compared to that of wild-type and TG2-KO mice, although the differ nce was ot tatistically
significant (Figure 3B).
2.4. In TG3KO Mouse Epidermis, Imiquimod Treatment leads to Thickening of the Spinous Layer and to
Reduced Organization of the Granular Compartment
To eval ate the cont ibution of the different epidermal layers to the thickened epid rmis observe
in psoriatic TG3KO m use skin, we performed immunofluorescence analysis of four epidermal
differentiation markers, namely, p63, loricrin, filaggrin, and keratin 10, in the skin of controls and
imiquimod-treated WT, TG2KO, and TG3KO mice. As shown in Figure 4, p63 protein, a marker of the
proliferative compartment, was detected in the basal layers of all sections, while the two keratinocyte
late differentiation markers filaggrin and loricrin were detected in the granular and upper granular
compartments, respectively. In particular, we observed a more diffuse and disorganized distribution
of loricrin in the psoriatic epidermis of TG3KO mice than in all other sections, probably due to a
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lack of TG3 crosslinking activity and to the consequent aberrant epidermal structure in these mice.
Interestingly, imiquimod treatment led to a considerable thickening of the spinous layer in all of the
treated mice, especially in TG3KO mice, as evidenced by the fluorescence labelling of keratin 10, a
marker of the epidermal spinous layer. This observed hyperkeratosis might be the result of an increased
permeability and sensitivity of TG3KO mouse skin to the psoriasis-inducing drug.
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3. Discussion
The cornified envelope, a tight and membranous structure formed by highly crosslinked proteins
and lipids, co fers the unique characteristic of a strong barrier against physical, chemical, and microbial
insults to the outermost layer of the epidermis. In the final stages of keratinocyte terminal differentiation,
during CE generation, substrates such as loricrin, filaggrin, involucrin, trichohyalin, small proli e-rich
protei s, and keratins are crosslinked intracellularly by three transglutaminases (TG1, TG3 and TG5) [3].
Alt ugh it has been estimated t at TG3 supports almost 75% of epidermal TG3 activity [40], its precise
contrib tion to the synthesis of the CE has not yet been well defined in vivo. Indeed, except for
impaired hair development, TG3KO mice do not show evident morphological abnormalities and have
an apparently ormal cutaneous structure and skin b rrier [12]. However, the epidermal barrier of
TG3KO ice appeared slightly dysfunctional upon ch lle ge, including increased susceptibility to
hapten FITC uptake or increased sensitivity to UV radiation [15,16]
TG2 is expressed in ll epidermal layers, although its function in epidermal homeostasis is
dispensable [21,22]. Dysregulation of pro-inflammatory TG2 activity elicits several inflammatory
disorders [28–30,41]. TG2 is involved in activation of the inflammatory res onse in stressed tissues,
where it stimulates both the release of inflammatory cytokines/chemokines and the recruit ent of
inflammatory cells into the stressed area [18,28,33]. In this study, we demonstrated that TG3 is necessary
for proper cutaneous barri r formation and that its ablatio in TG3KO mice increas d epid rmal
susceptibility to the psoriasis-inducing drug imiquimod. We also confirme previous data obtained in
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TG2KO mice, since TG2 gene deletion did not affect skin structure and resulted in indistinguishability
from WT mice in the context of psoriasis. This latter result also suggests that TG2 is not involved in
psoriasis-induced skin inflammation.
Psoriasis is an autoimmune and inflammatory skin disease that is triggered by a hyperactivated
cellular immune system. Psoriatic cytokines, such as IL17, IFNγ, TNF-α, IL-22, and IL-23 are released
from cells of the acquired and innate immune system in the dermis and stimulate inflammation,
increased keratinocyte proliferation and aberrant keratinocyte differentiation that results in an inability
to generate a proper skin barrier [42]. We suggest that the hyperexpression of TG1 and TG3 mRNA
observed in our bioinformatic analysis of human psoriatic skin samples develops as a cause and/or a
substantial compensation mechanism for the defective keratinocyte differentiation and hyperkeratosis
observed in the inflamed psoriatic epidermis. Further database analysis confirmed increased TG1 and
TG3 mRNA levels in imiquimod-induced mouse psoriatic skin samples, thus suggesting a probable
beneficial dysregulation of these two genes in psoriasis. Conversely, TG5 and TG2 were unaffected by
psoriatic inflammation, since their mRNA levels remained consistent in both psoriatic and normal skin
biopsies. Our bioinformatic analysis was limited to mRNA levels only, and so no information was
obtained regarding the detection of protein levels and/or their activities.
To elucidate the importance of TG3 and TG2 activities in the generation of a functional CE, we
used the psoriatic imiquimod mouse model to test whether TG3KO mice and TG2KO mice display
altered responses to the imiquimod drug compared with those of WT mice. When topically applied as
a cream, imiquimod, a TLR7/8-stimulating compound, induces dermatitis that closely mimics psoriasis
with typical hallmarks such as erythema, skin thickening, scaling, and epidermal alterations such as
acanthosis and parakeratosis [38]. After 10 days of 5% imiquimod topical application on the shaved
back skin, TG3KO, TG2KO, and WT mice, as expected, developed typical psoriatic plaques with
markers that worsened with treatment time.
Grossly, psoriatic skin of TG3KO mice showed no macroscopic visual differences compared to
those of TG2KO and WT mice. The severity of the scaling and erythema had comparable values and
trends in the three groups throughout all treatment times, as displayed in their nearly overlapping
graphs. This apparent lack of major changes in the skin when TG3 is ablated is in agreement with
previous studies on TG3KO mice [12] and suggests that in the TG3KO epidermis, TG3 crosslinking
activity is probably largely compensated for by the TG1 and TG5 enzymes. A more in-depth analysis
at the histological level revealed a significantly thicker (+33%) epidermis in psoriatic TG3KO mice
compared to that of WT and TG2KO mice. We hypothesize that the absence of TG3 protein generates
an impaired and more fragile epidermal barrier structure that facilitates percutaneous absorption and
penetration of imiquimod through the skin. In this regard, our results are in agreement with Bognar [15]
and with our recent study on the more profound sensitivity of TG3KO skin to UV radiation [16]. It is
likely that higher levels of absorbed imiquimod in TG3KO mice intensify hyperproliferation and
abnormal keratinocyte differentiation as a cutaneous response to the psoriasis-inducing drug. Indeed,
the thicker spinous layer and the more disorganized granular layer observed in immunofluorescence
analysis of psoriatic TG3KO mouse skin are probably the result of a more pronounced incomplete
keratinocyte differentiation that therefore halted at the level of the spinous layer and failed to become
mature corneocytes. Loricrin is a TG3 substrate, and the observation of a diffuse pattern in TG3KO
mice indicated a defective epidermal crosslinking in these mice. In our model, the expected increase in
the hyperproliferative activity of keratinocytes in the basal layer of TG3KO mice was only modest, as
detected by the number of Ki67-positive cells and visualization of immunofluorescence of p63 in the
basal layer. This effect is probably due to the milder hyperproliferative power induced by the drug
compared to the strong autoimmune effect of the spontaneous disease. Conversely, in our histological
and immunofluorescence analyses, TG2KO skin sections were substantially indistinguishable from the
corresponding WT skin sections in both imiquimod-treated and control samples. These data suggest
that the inflammatory process associated with psoriatic disease is independent of TG2 expression
or activation. Furthermore, the TG2KO results confirmed our recent studies in TG2KO mice whose
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keratinocyte morphological analysis and amino acid biochemical composition were very similar to
those of WT mice and indicate that the activity of the TG2 enzyme is not necessary for CE assembly
and the skin barrier [22].
4. Materials and Methods
4.1. Animal Studies
C57BL/6-TG2KO and C57BL/6-TG3KO mice were generated in our laboratory [21]. All mice used
in this study were bred in the animal facility of the University of Roma “Tor Vergata” under specific
pathogen-free conditions. All experiments were approved by the Institutional Animal Care and Use
Committee (IACUC) and were carried out according to the Italian and European rules (D.L.116/92; C.E.
609/86; European Directive 2010/63/EU). For mice experiments licence n◦ 817/2016PR (Italian Ministry
of Health). Male mice at 8 weeks of age were shaved using an electric shaver on the back skin and
received topical applications of imiquimod (3.125 mg) from a commercially available cream (5%) daily
for 10 days (Aldara; 3M Pharmaceuticals, St. Paul, MN, USA).
4.2. Scoring the Severity of Dermatitis
The degree of (1) erythema, (2) scaling, and (3) thickening was calculated as 0 (none), 1 (minor),
2 (moderate), 3 (severe), or 4 (very severe). The cumulative dermatitis grade (erythema plus scaling
plus thickening) indicated the severity of dermatitis (scale 0–4).
4.3. Histology and Immunostaining
For haematoxylin and eosin staining, 3 µm FFPE (Formalin-Fixed Paraffin-Embedded) sections
were dewaxed, rehydrated, stained in Mayer’s haematoxylin for 4 min, washed with tap water for 10 min,
and then stained with eosin for 40 sec, followed by a rapid wash in water. The slides were dehydrated,
mounted, and scanned using a 40× objective in a Ventana iCoreo scanner (Ventana, Oro Valley, AZ, USA).
For Ki67 immunohistochemical staining, 3 µm FFPE sections were dewaxed, rehydrated, and blocked
for 20 min in 0.3% hydrogen peroxide solution in methanol. Then, the slides were boiled in a microwave
for 10 min in 0.01 M sodium citrate buffer (pH 6.0), blocked with 5% goat serum in PBS for 30 min,
and incubated for 40 min with anti-Ki67 antibody (D2H10, 1:300, Cell Signaling, Leiden, Netherlands).
The signal was detected using an UltraTek HRP anti-polyvalent DAB staining system (ScyTek, Logan,
UT, USA), and then the slides were counterstained with haematoxylin for 10 sec, followed by a wash
in tap water, dehydration, and mounting. IL-22 and IL-17A staining was performed using anti IL-22
antibody (NB100-733, 1:250, Novus Biologicals LLC, Centennial, USA) and IL-17A antibody (217359,
1:50, Abcam, Cambdridge, UK), respectively. For immunofluorescence staining, 10 µm cryosections
were fixed in 4% paraformaldehyde for 10 min, permeabilized in a 0.1% PBS/Tween-20 solution for 10
min, blocked with 5% goat serum in PBS for 30 min, and incubated with primary antibodies overnight.
The following antibodies were used: anti-p63 (D2K8x, 1:300, Cell Signaling), anti-Loricrin (Poly19051,
1:300, BioLegend, San Diego, CA, USA), anti-filaggrin (PRB-417P, 1:300, Covance, Princeton, NJ, USA),
and anti-keratin 10 (PRB-159P, 1:1000, Covance). Then, the samples were washed and incubated with
anti-rabbit AlexaFluor-568 antibody (1:1000, Invitrogen, Carlsbad, CA, USA) together with 1 µg/mL
DAPI (Sigma, St. Louis, MO, USA) for nuclear DNA staining. Images were acquired by a Nikon A1
confocal laser microscope using NIS elements software (Nikon, Tokyo, Japan).
4.4. Bioinformatic Analysis
Normalized values of mRNA expression in the psoriasis-affected skin samples were obtained
from the NCBI GEO portal (Accession numbers: GSE13355, GSE27628, GSE6710, GSE14905, GSE78023,
and GSE63741).
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4.5. Statistical Analysis
All statistical analyses were performed using GraphPad Prism 7.0 Software (San Diego, CA, USA).
Two-tailed, unpaired Student’s t-tests were used for analysis of significant differences between two
groups. Values of p < 0.05 were considered significant.
5. Conclusions
In the present study, we determined whether TG2 and TG3 are normally involved in the
maintenance of skin barrier integrity and whether inflammatory processes modify the skin response
to imiquimod-induced psoriasis. Our findings suggest that TG3 is crucial in the maintenance of a
physiological cornified envelope in the stratum corneum and that its depletion sensitized mouse skin to
the action of imiquimod, as demonstrated by H&E, IF, and Ki67 staining. In contrast, TG2KO mouse skin
responded similarly to that of WT to imiquimod application, confirming the minor role of TG2 in skin
barrier formation. Moreover, our data indicates, for the first time, that the pro-inflammatory properties
of TG2 do not contribute to the onset of psoriatic disease, which is thus a TG2-independent process.
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